riv4
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Nov 10, 2022 (NCT05513391)
Timeline
Indications
Mechanism of action
- Influenza virusImmunity, active
Influenza virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06850051 | Phase 1 | Mar 19, 2025 | Sanofi |
| NCT05513391 | Phase 3 | Nov 10, 2022 | Sanofi-Aventis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 1 | 1 | 1 | 2025 |
| Sanofi-Aventis | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1